Blis Technologies Limited Ordinary Shares
BLT.NZXHealth Care
Blis is an NZX-listed manufacturer of advanced probiotic strains that enable the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and gum health. Combining innovation with evidence-based research has enabled the company to develop a range of products containing two strains of probiotic bacteria - BLIS K12 TM and BLIS M18 TM. Both of these strains occur naturally in the oral cavity however, only around 2% of the population have these healthy bacteria at levels high enough to be effective. BLIS products have received regulatory approvals for sale throughout New Zealand, Australia, Asia, Europe and the USA. Brand names include ThroatGuard PRO, DailyDefence, TravelProtect, HoneyBlis, FreshBreath and ToothGuard. Blis probiotics have a significant body of evidence which is constantly growing as more clinical trials are completed. Blis probiotics have been included in more than 40 clinical trials to date. The company's origins lie in research undertaken by Professor Emeritus John Tagg of the Microbiology Department at the University of Otago in New Zealand who found that Salivaricin B, a substance which acts as a natural antibiotic, controls streptococcal throat infections. Blis Technologies commenced business in August 2000 when it acquired the University's collection of several thousand bacteriocin-producing organisms. It listed on NZX in 2001.
Market Data
$0.017
0.0%$21.7M
34.0x
$0.001
0.00%
-0.0%
Latest Earnings
Strong revenue and underlying earnings growth
21 May 2026
BLIS Technologies reported FY26 revenue of NZD$14.7m, up 16% on the prior year, driven by strong B2B ingredient and private label growth. Reported EBITDA declined slightly to $0.9m due to a one-off $0.9m supply chain cost increase, but underlying EBITDA of $1.8m and underlying NPAT of $1.6m represent 83% and 90% improvements respectively. The company enters FY27 with confidence, supported by strengthened partnerships, a resolved IP dispute, advancing China regulatory pathway, and growing demand for science-backed oral probiotics. Key points: Revenue grew 16% to NZD$14.7m, driven by B2B ingredient revenue up 17% to $7.3m and private label revenue up 67% to $1.3m; Underlying EBITDA of $1.8m (up 83% on pcp) and underlying NPAT of $1.6m (up 90% on pcp) demonstrate strong earnings power excluding a one-off supply chain cost; Strong balance sheet with $8.5m in cash and short-term deposits and positive operating cash flow of $1.8m
Recent Announcements
Strong revenue and underlying earnings growth
BLIS Technologies reported FY26 revenue of NZD$14.7m, up 16% on the prior year, driven by strong B2B ingredient and private label growth. Reported EBITDA declined slightly to $0.9m due to a one-off $0.9m supply chain cost increase, but underlying EBITDA of $1.8m and underlying NPAT of $1.6m represent 83% and 90% improvements respectively. The company enters FY27 with confidence, supported by strengthened partnerships, a resolved IP dispute, advancing China regulatory pathway, and growing demand for science-backed oral probiotics. Key points: Revenue grew 16% to NZD$14.7m, driven by B2B ingredient revenue up 17% to $7.3m and private label revenue up 67% to $1.3m; Underlying EBITDA of $1.8m (up 83% on pcp) and underlying NPAT of $1.6m (up 90% on pcp) demonstrate strong earnings power excluding a one-off supply chain cost; Strong balance sheet with $8.5m in cash and short-term deposits and positive operating cash flow of $1.8m
Strong YTD performance
BLIS Technologies Limited reported strong nine-month revenue of $10.8m (up 17% year-over-year) despite Q3 revenue of $3.1m being 3% down, with full-year revenue forecast to exceed $14m and reported EBITDA expected between $0.8m-$1.1m.
Changes in BLIS Board
BLIS Technologies Limited announced that Paul Munro will join as an Independent Non-Executive Director effective March 1, 2026, replacing Geoff Plunket who is retiring after approximately eight years on the board.
Strong revenue and underlying earnings growth
BLIS Technologies delivered strong HY26 results with revenue of NZD $7.7M, up 28% on the prior corresponding period, driven by 39% B2B growth and 10% B2C growth. EBITDA of $0.5M was up $0.2M on pcp, though earnings were impacted by a one-off supply chain cost increase of $0.8M; on an underlying basis, EBITDA was $1.3M, up $1.0M on pcp. NPAT grew 83% to $0.419M, and FY26 full-year revenue growth is guided at 10–15% on FY25. Key points: Revenue of NZD $7.7M, up 28% on pcp, with both B2B and B2C channels recording double-digit growth; B2B revenue of $5.3M, up 39% on pcp, representing 68% of total revenue; EMEA ingredient revenue surged 83% to $3.1M; Underlying EBITDA of $1.3M (excluding one-off $0.8M supply chain cost), up $1.0M on pcp, reflecting strong operational leverage
2025 Annual Shareholder Meeting Results Announcement
Blis Technologies Limited held its Annual Shareholder Meeting on 21 August 2025, where all four resolutions were passed with strong shareholder support. The resolutions included the re-election of two directors, authorisation of auditor remuneration, and an amendment to the company's constitution. This announcement contains no financial results or earnings data. Key points: All four resolutions passed with strong shareholder support; Amelia (Aimee) McCammon re-elected as Director with 99.85% of votes in favour; Dr Alison Stewart re-elected as Director with 99.87% of votes in favour
Revenue and earnings growth
BLIS Technologies reported FY25 revenue of NZD $12.6m, up 10% on the prior year, driven by solid growth in finished product sales and B2C channels including 30% growth in Amazon US sales. EBITDA of $1.0m exceeded guidance of $0.6m-$0.8m (up 26% on FY24), while net profit grew 30% to $0.8m, supported by strong operating cash flow of $1.8m. The company enters FY26 with cautious optimism, though ongoing IP negotiations with its largest European customer and supply chain changes with Fonterra present near-term uncertainties. Key points: Revenue grew 10% to NZD $12.6m, with B2C revenue up 29% to $4.5m representing 36% of total revenue, driven by 30% growth in Amazon US sales ($2.0m) and a new China CBEC customer; EBITDA of $1.0m exceeded guidance range of $0.6m-$0.8m (up 26% on FY24 $0.8m), with cost savings from delayed China regulatory spend; Net profit grew 30% to $0.838m (FY24 $0.6m) and operating cash flow strengthened 64% to $1.8m (FY24 $1.1m)
Get real-time alerts for BLT
Receive AI-powered earnings summaries and instant notifications when Blis Technologies Limited Ordinary Shares releases results.
Register Free